Interaction Checker

Alosetron etkileşimleri

Alosetron (Lotronex) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 88 belgelenmiş etkileşim var: 11 majör, 42 orta, 3 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 32 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Alosetron nasıl görünür

6 sürümün tümü
Alosetron 1 mg tablet: mavi, oval, 11 mm, bir yüzünde GX, diğer yüzünde CT1 baskısı var.
GX / CT1
1 mg · mavi · oval · 11 mm
Sebela
Alosetron 0.5 mg tablet: beyaz, oval, 11 mm, bir yüzünde GX, diğer yüzünde EX1 baskısı var.
GX / EX1
0.5 mg · beyaz · oval · 11 mm
Sebela
Alosetron 0.5 mg tablet: beyaz, oval, 11 mm, üzerinde AN248 baskısı var.
AN248
0.5 mg · beyaz · oval · 11 mm
Amneal
Alosetron 1 mg tablet: mavi, oval, 11 mm, üzerinde AN249 baskısı var.
AN249
1 mg · mavi · oval · 11 mm
Amneal

Çizimler, FDA etiketlerindeki ürün bilgilerinden oluşturulmuştur: renk, şekil, boyut ve baskı. 6 firmaya ait 6 belgelenmiş sürüm.

Etikete göre etkileşimler

Majör etkileşimler (11)

  • Deferasiroksdemir takviyesiMajör

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron etiketi, Kontrendikasyonlar)

  • FluvoksaminSSRIMajör

    Concomitant use of fluvoxamine ( 4.3 ) (Alosetron etiketi, Kontrendikasyonlar)

  • Kannabidiol (reçeteli)antikonvülsanMajör

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron etiketi, Kontrendikasyonlar)

  • LevofloksasinflorokinolonMajör

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (Alosetron etiketi, İlaç etkileşimleri)

  • MeksiletinantiaritmikMajör

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron etiketi, Kontrendikasyonlar)

  • MoksifloksasinflorokinolonMajör

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (Alosetron etiketi, İlaç etkileşimleri)

  • OfloksasinflorokinolonMajör

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (Alosetron etiketi, İlaç etkileşimleri)

  • SimetidinH2 blokeriMajör

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron etiketi, Kontrendikasyonlar)

  • SiprofloksasinflorokinolonMajör

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron etiketi, Kontrendikasyonlar)

  • Viloksazinnoradrenalin geri alım inhibitörüMajör

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron etiketi, Kontrendikasyonlar)

  • ZileutonCYP1A2 inhibitörüMajör

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron etiketi, Kontrendikasyonlar)

Orta düzey etkileşimler (42)

  • AmiodaronantiaritmikOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • AprepitantCYP3A4 inhibitörüOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • AtazanavirantiretroviralOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • DarunavirantiretroviralOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Darunavir ve kobisistatantiretroviralOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Diltiazemkalsiyum kanal blokeriOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • DronedaronantiaritmikOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • EfavirenzantiretroviralOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Efavirenz, lamivudin ve tenofovirantiretroviralOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • EluksadolinopioidOrta

    Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (Eluksadolin etiketi, İlaç etkileşimleri)

  • Elvitegravir, kobisistat, emtrisitabin ve tenofovirantiretroviralOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Eritromisinmakrolid antibiyotikOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • EverolimusimmünosüpresanOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Flukonazolazol antifungalOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • FosamprenavirantiretroviralOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • FosaprepitantCYP3A4 inhibitörüOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • İmatinibCYP3A4 inhibitörüOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • İtrakonazolazol antifungalOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • İvakaftorCYP3A4 inhibitörüOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • İzoniazidantibiyotikOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Ketokonazolazol antifungalOrta

    Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%. (Alosetron etiketi, İlaç etkileşimleri)

  • Klaritromisinmakrolid antibiyotikOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • LeflunomidimmünosüpresanOrta

    In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (Leflunomid etiketi, İlaç etkileşimleri)

  • LenakapavirantiretroviralOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Lopinavir ve ritonavirantiretroviralOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • MifepristonCYP3A4 inhibitörüOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Mirabegronbeta adrenerjik agonistOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • NefazodonantidepresanOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Nirmatrelvir ve ritonavirantiviralOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • PalbosiklibCYP3A4 inhibitörüOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • PerampanelantikonvülsanOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Posakonazolazol antifungalOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • PrimakinantimalaryalOrta

    Effects of Primaquine on the Pharmacokinetics of Other Drugs CYP1A2 Substrates Published clinical and non-clinical reports indicate primaquine inhibits CYP1A2 enzyme activity and thus may lead to increased exposure of CYP1A2 substrate drugs (e.g., duloxetine, alosetron, theophylline and tizanidine) when co-administered with Primaquine phosphate Tablets. (Primakin etiketi, İlaç etkileşimleri)

  • RanolazinQT aralığını uzatan ilaçOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • RitonavirantiretroviralOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • SenobamatantikonvülsanOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • SiklosporinimmünosüpresanOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Suvoreksantsedatif-hipnotikOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • TeriflunomidimmünosüpresanOrta

    In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (Teriflunomid etiketi, İlaç etkileşimleri)

  • Tikagrelorantitrombosit ilaçOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Verapamilkalsiyum kanal blokeriOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

  • Vorikonazolazol antifungalOrta

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

Minör değinmeler (3)

  • HidralazinvazodilatörMinör

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (Alosetron etiketi, İlaç etkileşimleri)

  • İzosorbid dinitrat ve hidralazinnitratMinör

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (Alosetron etiketi, İlaç etkileşimleri)

  • ProkainamidantiaritmikMinör

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (Alosetron etiketi, İlaç etkileşimleri)

Anlamlı etkileşim olmadığı bildirilenler (32)

  • Allopurinolksantin oksidaz inhibitörüEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

  • AminofilinmetilksantinEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

  • Butalbital, aspirin ve kafeinbarbitüratEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

  • Butalbital, aspirin, kafein ve kodeinbarbitüratEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

  • Butalbital, parasetamol ve kafeinbarbitüratEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

  • Butalbital, parasetamol, kafein ve kodeinbarbitüratEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

  • Desogestrel ve etinilestradioloral kontraseptifEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Drospirenon ve etinilestradioloral kontraseptifEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Ergotamin ve kafeinergot alkaloidiEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

  • Esterifiye östrojenler ve metiltestosteronöstrojenEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • EstradiolöstrojenEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Estradiol ve dienogestoral kontraseptifEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Estradiol ve noretisteronöstrojenEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Etinodiol diasetat ve etinilestradioloral kontraseptifEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Etonogestrel ve etinilestradiolöstrojenEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Febuksostatksantin oksidaz inhibitörüEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

  • FulvestrantöstrojenEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Konjuge östrojenleröstrojenEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Konjuge östrojenler ve bazedoksifenöstrojenEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • LevonorgestrelprogestinEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Levonorgestrel ve etinilestradioloral kontraseptifEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • MedroksiprogesteronprogestinEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • MegestrolprogestinEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Norelgestromin ve etinilestradiolöstrojenEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • NoretisteronprogestinEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Noretisteron ve etinilestradioloral kontraseptifEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Norgestimat ve etinilestradioloral kontraseptifEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Norgestrel ve etinilestradioloral kontraseptifEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • Orfenadrin, aspirin ve kafeinkas gevşeticiEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

  • PentoksifilinmetilksantinEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

  • ProgesteronprogestinEtkileşim yok

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron etiketi, İlaç etkileşimleri)

  • TeofilinmetilksantinEtkileşim yok

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Alosetron ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.